# CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency

> **NCT07015801** · NA · ACTIVE_NOT_RECRUITING · sponsor: **University of Calgary** · enrollment: 1 (actual)

## Conditions studied

- Cytomegalovirus Viremia
- Cytomegalovirus Pneumonia
- T-Lymphocyte Immunodeficiency

## Interventions

- **BIOLOGICAL:** CMV-VST

## Key facts

- **NCT ID:** NCT07015801
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-04
- **Final completion:** 2040-04
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07015801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07015801, "CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07015801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*